The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
Harvey Fierstein shared how he lost 120 pounds. He says he is a “great believer” in weight loss drugs like Zepbound and ...
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...